Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Shares Gap Down – What’s Next?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $10.1350, but opened at $9.43. Greenland Mines Ltd. Common Stock shares last traded at $8.56, with a volume of 41,940 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GRML shares. Weiss Ratings downgraded shares of Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Greenland Mines Ltd. Common Stock has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Price Performance

The company has a fifty day simple moving average of $0.22 and a 200-day simple moving average of $0.35. The company has a market cap of $1.43 billion, a P/E ratio of -28.22 and a beta of 7.13.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last released its quarterly earnings data on Monday, August 17th. The company reported ($0.03) earnings per share for the quarter.

Insider Buying and Selling at Greenland Mines Ltd. Common Stock

In related news, Director Riad Hussein El-Dada sold 175,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $0.23, for a total value of $40,250.00. Following the transaction, the director owned 175,000 shares of the company’s stock, valued at approximately $40,250. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jason David Sawyer acquired 240,000 shares of the business’s stock in a transaction on Wednesday, July 22nd. The shares were bought at an average price of $0.23 per share, for a total transaction of $55,200.00. Following the acquisition, the director owned 240,000 shares in the company, valued at approximately $55,200. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brummer Multi Strategy AB purchased a new position in shares of Greenland Mines Ltd. Common Stock in the fourth quarter worth approximately $175,000. Geode Capital Management LLC lifted its position in shares of Greenland Mines Ltd. Common Stock by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after acquiring an additional 167,905 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Greenland Mines Ltd. Common Stock in the 4th quarter valued at approximately $126,000. Jane Street Group LLC purchased a new stake in shares of Greenland Mines Ltd. Common Stock in the 4th quarter valued at approximately $64,000. Finally, XTX Topco Ltd boosted its stake in Greenland Mines Ltd. Common Stock by 101.2% in the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after purchasing an additional 80,768 shares during the period. 20.07% of the stock is currently owned by institutional investors and hedge funds.

About Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.